 Rebecca Wolsky
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Struma Ovarii | 3 | 2026 | 8 | 1.900 |
Why?
| | Ovarian Neoplasms | 6 | 2026 | 586 | 1.820 |
Why?
| | Endometrial Neoplasms | 6 | 2026 | 208 | 1.790 |
Why?
| | Thyroid Neoplasms | 3 | 2026 | 345 | 1.400 |
Why?
| | Immunohistochemistry | 4 | 2026 | 1716 | 0.770 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 189 | 0.740 |
Why?
| | Carcinoma, Endometrioid | 2 | 2022 | 51 | 0.680 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2026 | 549 | 0.670 |
Why?
| | Biomarkers, Tumor | 4 | 2026 | 1313 | 0.630 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2020 | 267 | 0.570 |
Why?
| | Squamous Intraepithelial Lesions of the Cervix | 1 | 2018 | 2 | 0.570 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2018 | 19 | 0.550 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 73 | 0.550 |
Why?
| | Ki-67 Antigen | 1 | 2018 | 117 | 0.540 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 67 | 0.530 |
Why?
| | Hyperplasia | 1 | 2018 | 174 | 0.530 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2017 | 14 | 0.520 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 28 | 0.510 |
Why?
| | Carcinosarcoma | 1 | 2017 | 23 | 0.510 |
Why?
| | Mutation | 5 | 2026 | 4089 | 0.510 |
Why?
| | Sentinel Lymph Node | 1 | 2017 | 49 | 0.500 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2017 | 118 | 0.490 |
Why?
| | Actinomyces | 1 | 2015 | 3 | 0.460 |
Why?
| | Earache | 1 | 2015 | 6 | 0.460 |
Why?
| | Actinomycosis | 1 | 2015 | 5 | 0.460 |
Why?
| | Maxillary Sinusitis | 1 | 2015 | 6 | 0.460 |
Why?
| | beta Catenin | 4 | 2023 | 252 | 0.440 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2026 | 529 | 0.360 |
Why?
| | Neoplasm Grading | 5 | 2025 | 307 | 0.310 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 732 | 0.270 |
Why?
| | Wnt Proteins | 2 | 2021 | 133 | 0.250 |
Why?
| | DNA Copy Number Variations | 1 | 2026 | 183 | 0.220 |
Why?
| | Female | 17 | 2026 | 78271 | 0.220 |
Why?
| | DNA Polymerase II | 1 | 2023 | 35 | 0.200 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2024 | 84 | 0.200 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 36 | 0.200 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2023 | 19 | 0.200 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 52 | 0.200 |
Why?
| | Iodine Radioisotopes | 1 | 2022 | 136 | 0.180 |
Why?
| | Humans | 20 | 2026 | 144759 | 0.170 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 210 | 0.170 |
Why?
| | Cervix Uteri | 1 | 2020 | 50 | 0.160 |
Why?
| | Prognosis | 3 | 2024 | 4282 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 67 | 0.160 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2019 | 58 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 421 | 0.150 |
Why?
| | Granular Cell Tumor | 1 | 2018 | 8 | 0.140 |
Why?
| | Phyllodes Tumor | 1 | 2018 | 2 | 0.140 |
Why?
| | Neoplasm Staging | 2 | 2025 | 1462 | 0.140 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.140 |
Why?
| | Fallopian Tubes | 1 | 2018 | 33 | 0.140 |
Why?
| | Cell Proliferation | 2 | 2018 | 2496 | 0.140 |
Why?
| | Organotechnetium Compounds | 1 | 2017 | 12 | 0.130 |
Why?
| | Colorimetry | 1 | 2017 | 12 | 0.130 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2017 | 15 | 0.130 |
Why?
| | Mucous Membrane | 1 | 2018 | 127 | 0.130 |
Why?
| | Indocyanine Green | 1 | 2017 | 42 | 0.130 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 462 | 0.130 |
Why?
| | Epithelium | 1 | 2018 | 314 | 0.130 |
Why?
| | Coloring Agents | 1 | 2017 | 93 | 0.130 |
Why?
| | Surgical Oncology | 1 | 2017 | 30 | 0.130 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 69 | 0.130 |
Why?
| | Ovary | 1 | 2018 | 228 | 0.120 |
Why?
| | Lymph Node Excision | 1 | 2017 | 173 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 339 | 0.120 |
Why?
| | Middle Aged | 7 | 2026 | 35875 | 0.110 |
Why?
| | Maxillary Sinus | 1 | 2015 | 11 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1953 | 0.110 |
Why?
| | Gynecology | 1 | 2017 | 178 | 0.110 |
Why?
| | Aged, 80 and over | 2 | 2026 | 8265 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2020 | 928 | 0.100 |
Why?
| | HMGA2 Protein | 1 | 2013 | 10 | 0.100 |
Why?
| | Societies, Medical | 1 | 2017 | 887 | 0.090 |
Why?
| | Aged | 5 | 2026 | 25913 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1455 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2018 | 1125 | 0.090 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 161 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2018 | 847 | 0.080 |
Why?
| | Prospective Studies | 1 | 2023 | 7990 | 0.080 |
Why?
| | Prostatic Neoplasms | 1 | 2018 | 974 | 0.080 |
Why?
| | Receptors, Progesterone | 1 | 2013 | 356 | 0.080 |
Why?
| | Combined Modality Therapy | 2 | 2025 | 1266 | 0.080 |
Why?
| | Paired Box Transcription Factors | 1 | 2010 | 43 | 0.080 |
Why?
| | SOXE Transcription Factors | 1 | 2010 | 22 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 623 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2010 | 75 | 0.070 |
Why?
| | Disease Management | 2 | 2025 | 645 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2878 | 0.070 |
Why?
| | Adult | 4 | 2026 | 40449 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2021 | 3540 | 0.050 |
Why?
| | Melanoma | 1 | 2010 | 761 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2023 | 322 | 0.050 |
Why?
| | RNA | 2 | 2023 | 940 | 0.040 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 44 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 80 | 0.040 |
Why?
| | Hospitals, General | 1 | 2020 | 26 | 0.040 |
Why?
| | Papanicolaou Test | 1 | 2020 | 35 | 0.040 |
Why?
| | Vaginal Smears | 1 | 2020 | 55 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2452 | 0.040 |
Why?
| | Imidazoles | 1 | 2021 | 254 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 348 | 0.040 |
Why?
| | Chromatin | 1 | 2023 | 561 | 0.040 |
Why?
| | Dynactin Complex | 1 | 2018 | 5 | 0.040 |
Why?
| | Sequestosome-1 Protein | 1 | 2018 | 15 | 0.040 |
Why?
| | Oncogene Fusion | 1 | 2018 | 11 | 0.040 |
Why?
| | Kallikreins | 1 | 2018 | 25 | 0.030 |
Why?
| | GATA3 Transcription Factor | 1 | 2018 | 22 | 0.030 |
Why?
| | Metaplasia | 1 | 2018 | 57 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 432 | 0.030 |
Why?
| | Cell Survival | 1 | 2021 | 1098 | 0.030 |
Why?
| | Recurrence | 1 | 2021 | 1135 | 0.030 |
Why?
| | Prostate-Specific Antigen | 1 | 2018 | 161 | 0.030 |
Why?
| | Pyridines | 1 | 2021 | 605 | 0.030 |
Why?
| | Risk Assessment | 1 | 2026 | 3671 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2089 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2026 | 17066 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1075 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5408 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11679 | 0.020 |
Why?
| | PAX3 Transcription Factor | 1 | 2010 | 17 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 688 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 851 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2182 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2010 | 635 | 0.020 |
Why?
| | Child, Preschool | 1 | 2018 | 11787 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2847 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 14105 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2430 | 0.010 |
Why?
| | Male | 2 | 2018 | 72315 | 0.010 |
Why?
| | Adolescent | 1 | 2018 | 22428 | 0.010 |
Why?
| | Child | 1 | 2018 | 22633 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18339 | 0.010 |
Why?
| | Animals | 1 | 2013 | 38058 | 0.000 |
Why?
|
|
Wolsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|